Skip to main
RANI

RANI Stock Forecast & Price Target

RANI Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rani Therapeutics Holdings Inc has demonstrated the capability of its RaniPill technology to deliver biologics orally, achieving comparable biological activity and enhanced bioavailability, with RT-114 showing a relative bioavailability of approximately 111% compared to subcutaneous dosing. The partnership with Chugai provides additional validation from a significant industry player and positions Rani to capitalize on the expanding market for oral obesity therapies, highlighted by strong M&A activity in 2026. Additionally, the company is well-capitalized with a cash runway extending through 2028, allowing for continued investment in the advancement of its technologies without compromising its financial stability.

Bears say

Rani Therapeutics Holdings Inc faces significant challenges that contribute to a negative outlook on its stock, primarily linked to uncertainties in its revenue forecasts and market competition. The company's reliance on achieving assumed reimbursement levels is critical, and any failure to meet these assumptions could adversely impact financial projections. Additionally, while the safety profile of the RaniPill platform is deemed promising, concerns regarding the potential for clinical trial failures and the modest valuation ascribed to the platform indicate that the market may not fully recognize the associated risks and the current undervaluation of these assets.

RANI has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rani Therapeutics Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rani Therapeutics Holdings (RANI) Forecast

Analysts have given RANI a Strong Buy based on their latest research and market trends.

According to 3 analysts, RANI has a Strong Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rani Therapeutics Holdings (RANI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.